Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

FDA Working 'Very Hard' To Get Biosimilars Guidances Completed, CDER Chief Tells Hearing

This article was originally published in SRA

Executive Summary

Under fire from lawmakers, Janet Woodcock, director of the US Food and Drug Administration's Center for Drug Evaluation and Research, took cover by insisting the reason the agency has yet to issue or finalize some of the most important biosimilars guidance documents industry has been waiting on – specifically, those on interchangeability and labeling – is because regulators must first "get the science right."

Advertisement
Advertisement
UsernamePublicRestriction

Register